ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Cell Cycle >Aurora Kinase Inhibitors >MLN-8237


MLN-8237 Suppliers list
Company Name: Capot Chemical Co.,Ltd.
Tel: +86-571-85586718
Products Intro: Product Name:MLN-8237
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Tel: +86 21 5161 9050/ 5187 7795
Products Intro: CAS:1028486-01-2
Purity:0.99 Package:5MG;10MG;50MG;100MG,1G,5G
Company Name: career henan chemical co
Tel: +86-371-86658258
Products Intro: Product Name:MLN-8237
Purity:98% Package:1KG;1USD
Company Name: Biochempartner
Tel: 0086-13720134139
Products Intro: Product Name:Alisertib
Purity:98% HPLC LCMS Package:10G;20G
Company Name: Hubei xin bonus chemical co. LTD
Tel: 86-13657291602
Products Intro: Product Name:MLN-8237
Purity:0.99 Package:5KG;1KG

Lastest Price from MLN-8237 manufacturers

  • MLN-8237
  • US $1.00 / KG
  • 2019-07-06
  • CAS:1028486-01-2
  • Min. Order: 1G
  • Purity: 98%
  • Supply Ability: 100KG
MLN-8237 Basic information
Description In vitro In vivo
Product Name:MLN-8237
Synonyms:Benzoic acid, 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxy-;MLN-8237 4-[[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid;alisertib (auroura A kinase inhibitor);4-[[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid;Fluorocyclopentenylcytosine;ALISERTIB (MLN8237);MLN 8237; MLN8237;MLN-8237;4-((9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-yl)amino)-2-meth;MLN-823
Product Categories:Inhibitor;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API
Mol File:1028486-01-2.mol
MLN-8237 Structure
MLN-8237 Chemical Properties
Boiling point 729.1±70.0 °C(Predicted)
density 1.43±0.1 g/cm3(Predicted)
Safety Information
MSDS Information
MLN-8237 Usage And Synthesis
DescriptionAlisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
In vitroMLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib.MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment.
In vivoMLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control.
Chemical PropertiesOff-White Solid
UsesAn Aurora kinase inhibitor, used to treat patients with advanced solid tumors.
MLN-8237 Preparation Products And Raw materials
Tag:MLN-8237(1028486-01-2) Related Product Information
Bortezomib Trametinib BI 2536 6-[2-[4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-ylamino]ethylamino]pyridine-3-carbonitrile Olaparib Barasertib (AZD1152-HQPA)